Biofrontera Stock Performance
| BFRI Stock | USD 0.88 0.03 3.53% |
On a scale of 0 to 100, Biofrontera holds a performance score of 3. The firm shows a Beta (market volatility) of 0.82, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Biofrontera's returns are expected to increase less than the market. However, during the bear market, the loss of holding Biofrontera is expected to be smaller as well. Please check Biofrontera's sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether Biofrontera's price patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Biofrontera are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite fairly inconsistent basic indicators, Biofrontera demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:20 | Last Split Date 2023-07-05 |
1 | Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis | 05/01/2025 |
2 | Biofrontera signals 2025 record revenue ambitions with new Ameluz patent and cost controls | 05/16/2025 |
3 | Biofrontera Inc. Q1 2025 Earnings Call Transcript | 05/20/2025 |
4 | Biofrontera Receives Nasdaq Non-Compliance Notice - TipRanks | 05/23/2025 |
5 | Acquisition by Hermann Luebbert of 113379 shares of Biofrontera at 4.77 subject to Rule 16b-3 | 05/29/2025 |
6 | Biofrontera Inc. Propylene Glycol-Free Patent Gains FDA Recognition BFRI Stock News | 06/03/2025 |
7 | Biofrontera AG Explores Strategic Changes with Biofrontera Inc. - TipRanks | 06/10/2025 |
8 | Biofrontera Inc. Engages in Strategic Talks with Biofront - GuruFocus | 06/12/2025 |
9 | Insider Trading | 06/30/2025 |
10 | Biofrontera stock rises after restructuring agreement with Biofrontera AG By Investing.com - Investing.com Nigeria | 07/01/2025 |
11 | Biofrontera files to sell 13.6M shares of common stock by selling shareholders - MSN | 07/17/2025 |
| Begin Period Cash Flow | 1.5 M | |
| Total Cashflows From Investing Activities | -3000.00 |
Biofrontera | Build AI portfolio with Biofrontera Stock |
Biofrontera Relative Risk vs. Return Landscape
If you would invest 81.00 in Biofrontera on April 20, 2025 and sell it today you would earn a total of 7.00 from holding Biofrontera or generate 8.64% return on investment over 90 days. Biofrontera is currently generating 0.2636% in daily expected returns and assumes 5.2203% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than Biofrontera, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biofrontera Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biofrontera's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biofrontera, and traders can use it to determine the average amount a Biofrontera's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0505
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BFRI | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.22 actual daily | 46 54% of assets are more volatile |
Expected Return
| 0.26 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Biofrontera is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biofrontera by adding it to a well-diversified portfolio.
Biofrontera Fundamentals Growth
Biofrontera Stock prices reflect investors' perceptions of the future prospects and financial health of Biofrontera, and Biofrontera fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biofrontera Stock performance.
| Return On Equity | -3.85 | ||||
| Return On Asset | -0.49 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.53) % | ||||
| Current Valuation | 11.4 M | ||||
| Shares Outstanding | 9.45 M | ||||
| Price To Book | 17.77 X | ||||
| Price To Sales | 0.22 X | ||||
| Revenue | 37.3 M | ||||
| Gross Profit | 20.24 M | ||||
| EBITDA | (14.44 M) | ||||
| Net Income | (17.76 M) | ||||
| Cash And Equivalents | 31.91 M | ||||
| Cash Per Share | 1.36 X | ||||
| Total Debt | 4.92 M | ||||
| Current Ratio | 3.16 X | ||||
| Book Value Per Share | 0.05 X | ||||
| Cash Flow From Operations | (10.27 M) | ||||
| Earnings Per Share | (0.81) X | ||||
| Market Capitalization | 8.33 M | ||||
| Total Asset | 22.1 M | ||||
| Retained Earnings | (117.41 M) | ||||
| Working Capital | 8.68 M | ||||
About Biofrontera Performance
By evaluating Biofrontera's fundamental ratios, stakeholders can gain valuable insights into Biofrontera's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biofrontera has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biofrontera has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 130.37 | 229.60 | |
| Return On Tangible Assets | (0.80) | (0.85) | |
| Return On Capital Employed | (1.71) | (1.79) | |
| Return On Assets | (0.80) | (0.84) | |
| Return On Equity | (4.01) | (4.21) |
Things to note about Biofrontera performance evaluation
Checking the ongoing alerts about Biofrontera for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biofrontera help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biofrontera had very high historical volatility over the last 90 days | |
| Biofrontera has some characteristics of a very speculative penny stock | |
| Biofrontera has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 37.3 M. Net Loss for the year was (17.76 M) with profit before overhead, payroll, taxes, and interest of 20.24 M. | |
| Biofrontera currently holds about 31.91 M in cash with (10.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 13.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Biofrontera files to sell 13.6M shares of common stock by selling shareholders - MSN |
- Analyzing Biofrontera's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biofrontera's stock is overvalued or undervalued compared to its peers.
- Examining Biofrontera's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biofrontera's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biofrontera's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biofrontera's stock. These opinions can provide insight into Biofrontera's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biofrontera Stock analysis
When running Biofrontera's price analysis, check to measure Biofrontera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera is operating at the current time. Most of Biofrontera's value examination focuses on studying past and present price action to predict the probability of Biofrontera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera's price. Additionally, you may evaluate how the addition of Biofrontera to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |